APA (7th ed.) Citation

(2018). The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease, including a placebo-treated noncarrier cohort.

Chicago Style (17th ed.) Citation

The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-dominant Alzheimer’s Disease, Including a Placebo-treated Noncarrier Cohort. 2018.

MLA (8th ed.) Citation

The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-dominant Alzheimer’s Disease, Including a Placebo-treated Noncarrier Cohort. 2018.